Ex­clu­sive: Strug­gling Ed­i­tas shops pre­clin­i­cal can­cer pipeline dur­ing its big makeover

Sto­ried CRISPR gene edit­ing pi­o­neer Ed­i­tas Med­i­cine $ED­IT is in ad­vanced dis­cus­sions re­gard­ing the sale of the pre­clin­i­cal on­col­o­gy line­up in its pipeline as the biotech works through a makeover of the com­pa­ny, its ex­ec­u­tive team and the drugs it hopes to take through the clin­ic, End­points News has learned.

Can­cer drugs sit on the bot­tom rung of the totem pole in Ed­i­tas’ R&D group, but in­cludes the iNK treat­ment ED­IT-202, which was re­cent­ly tout­ed by the biotech as a ther­a­py that fea­tured “dou­ble knock-in and dou­ble knock-out ed­its.” The pre­clin­i­cal pro­file of the nat­ur­al killer can­di­date of­fered a shot at prov­ing greater dura­bil­i­ty and per­sis­tence for an al­lo­gene­ic — or off-the-shelf ap­proach — against sol­id tu­mors, one of the holy grails in drug R&D these days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER